Fibrinogen to HDL-Cholesterol ratio as a predictor of mortality risk in patients with acute myocardial infarction.

Publisher: BioMed Central Country of Publication: England NLM ID: 101147696 Publication Model: Electronic Cited Medium: Internet ISSN: 1476-511X (Electronic) Linking ISSN: 1476511X NLM ISO Abbreviation: Lipids Health Dis Subsets: MEDLINE

Original Publication: [London] : BioMed Central, 2002-

Myocardial Infarction* ; Atherosclerosis*; Humans ; Cholesterol, HDL ; Retrospective Studies ; Fibrinogen ; Risk Factors ; Inflammation

Background: Acute myocardial infarction (AMI) is characterized by inflammation, oxidative stress, and atherosclerosis, contributing to increased mortality risk. High-density lipoprotein (HDL) takes a crucial part in mitigating atherosclerosis and inflammation through its diverse functionalities. Conversely, fibrinogen is implicated in the development of atherosclerotic plaques. However, the mortality risk predictive capacity of fibrinogen to HDL-cholesterol ratio (FHR) in AMI patients remains unexplored. This research aimed to evaluate the effectiveness of FHR for mortality risk prediction in relation to AMI.
Methods: A retrospective study involving 13,221 AMI patients from the Cardiorenal ImprovemeNt II cohort (NCT05050877) was conducted. Baseline FHR levels were used to categorize patients into quartiles. The assessment of survival disparities among various groups was conducted by employing Kaplan‒Meier diagram. Cox regression was performed for investigating the correlation between FHR and adverse clinical outcomes, while the Fine-Gray model was applied to evaluate the subdistribution hazard ratios for cardiovascular death.
Results: Over a median follow-up of 4.66 years, 2309 patients experienced all-cause death, with 1007 deaths attributed to cardiovascular disease (CVD). The hazard ratio (HR) and its 95% confidence interval (CI) for cardiac and all-cause death among individuals in the top quartile of FHR were 2.70 (1.99-3.65) and 1.48 (1.26-1.75), respectively, in comparison to ones in the first quartile, after covariate adjustment. Restricted cubic spline analysis revealed that FHR was linearly correlated with all-cause mortality, irrespective of whether models were adjusted or unadjusted (all P for nonlinearity > 0.05).
Conclusion: AMI patients with increased baseline FHR values had higher all-cause and cardiovascular mortality, regardless of established CVD risk factors. FHR holds promise as a valuable tool for evaluating mortality risk in AMI patients.
Trial Registration: The Cardiorenal ImprovemeNt II registry NCT05050877.
(© 2024. The Author(s).)

JAMA. 2009 Nov 11;302(18):1993-2000. (PMID: 19903920)
Eur Heart J. 2022 Mar 7;43(10):971-981. (PMID: 34508626)
Arq Bras Cardiol. 2016 Jan;106(1):56-61. (PMID: 26690693)
J Am Coll Cardiol. 2021 Feb 2;77(4):375-388. (PMID: 33509394)
Circulation. 2007 Nov 27;116(22):2634-53. (PMID: 17951284)
Atherosclerosis. 2013 May;228(1):247-8. (PMID: 23466074)
JAMA. 2008 Jun 4;299(21):2524-32. (PMID: 18523221)
Chin Med J (Engl). 2015 Jul 5;128(13):1732-7. (PMID: 26112712)
Circ Res. 2004 Oct 15;95(8):764-72. (PMID: 15486323)
Circulation. 2000 Oct 3;102(14):1634-8. (PMID: 11015340)
Arterioscler Thromb Vasc Biol. 2017 Jan;37(1):118-129. (PMID: 27879252)
Arterioscler Thromb Vasc Biol. 1998 Sep;18(9):1450-5. (PMID: 9743234)
J Int Adv Otol. 2021 Mar;17(2):91-95. (PMID: 33893776)
Arterioscler Thromb Vasc Biol. 1995 Nov;15(11):1987-94. (PMID: 7583580)
N Engl J Med. 2005 Apr 21;352(16):1685-95. (PMID: 15843671)
Eur Heart J Acute Cardiovasc Care. 2015 Feb;4(1):64-74. (PMID: 24833640)
Cardiovasc Res. 2014 Aug 1;103(3):362-71. (PMID: 24891399)
Semin Immunopathol. 2012 Jan;34(1):43-62. (PMID: 22037947)
Lipids Health Dis. 2020 Apr 4;19(1):59. (PMID: 32247314)
N Engl J Med. 2012 Nov 29;367(22):2089-99. (PMID: 23126252)
Am J Med. 1977 May;62(5):707-14. (PMID: 193398)
Atherosclerosis. 2007 Dec;195(2):e126-34. (PMID: 17336309)
Thromb Haemost. 2003 Apr;89(4):601-9. (PMID: 12669113)
Biochemistry (Mosc). 2023 Jan;88(Suppl 1):S39-S51. (PMID: 37069113)
Thromb Haemost. 1998 Nov;80(5):749-56. (PMID: 9843166)
Audiol Neurootol. 2010;15(2):111-5. (PMID: 19657186)
Thromb Res. 2008;122(1):1-12. (PMID: 17669476)
Curr Vasc Pharmacol. 2017;15(5):404-415. (PMID: 28155617)
J Am Coll Cardiol. 2018 Oct 23;72(17):2071-2081. (PMID: 30336831)
Cardiovasc Diabetol. 2021 Jul 16;20(1):143. (PMID: 34271936)
Blood. 2004 Nov 15;104(10):3221-7. (PMID: 15284110)
Lancet. 2012 Aug 11;380(9841):572-80. (PMID: 22607825)
JAMA. 2010 Dec 8;304(22):2503-12. (PMID: 21139111)
Heart. 2012 Aug;98(15):1160-5. (PMID: 22689713)
Turk Kardiyol Dern Ars. 2018 Jun;46(4):260-267. (PMID: 29853693)
Pol Merkur Lekarski. 2016 May;40(239):283-7. (PMID: 27234856)
Arterioscler Thromb Vasc Biol. 1998 Apr;18(4):621-5. (PMID: 9555868)
Arterioscler Thromb Vasc Biol. 2017 Mar;37(3):e13-e21. (PMID: 28228446)
Int J Mol Sci. 2021 Dec 24;23(1):. (PMID: 35008616)
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021. (PMID: 33309175)
Biochim Biophys Acta Mol Cell Biol Lipids. 2022 Jan;1867(1):159058. (PMID: 34624514)
J Atheroscler Thromb. 2010 Oct 27;17(10):1003-8. (PMID: 20551578)
Circulation. 2021 May 18;143(20):1935-1945. (PMID: 33840204)

BY012022066 Congzhuo Jia; 2020B1111170011 Ning Tan; KJ022021049 Yong Liu; No. Y0120220151 Jiyan Chen

Keywords: Acute myocardial infarction; Fibrinogen; HDL cholesterol; Inflammation

ClinicalTrials.gov NCT05050877

0 (Cholesterol, HDL)
9001-32-5 (Fibrinogen)

Date Created: 20240326 Date Completed: 20240327 Latest Revision: 20240328

20240329

PMC10962130

10.1186/s12944-024-02071-7

38528580